Aggressive LDL Lowering Strategy Dramatically Reduces Cardiovascular Events
A research team at Severance Hospital has identified a groundbreaking finding: an aggressive strategy for lowering low-density lipoprotein (LDL) cholesterol in patients with atherosclerotic cardiovascular disease significantly reduces major cardiovascular events.
The vital findings were presented at the 2026 American College of Cardiology annual scientific session and subsequently published in the New England Journal of Medicine.
The study revealed that aggressively targeting LDL cholesterol to below 55mg/dL decreased major cardiovascular events by over 30 percent in patients with atherosclerotic cardiovascular disease, in contrast to the conventional goal of 70mg/dL.
The Study's Objective
Patients diagnosed with atherosclerotic cardiovascular disease face a high risk of recurrent events such as myocardial infarction or stroke. While previous research has explored the effectiveness of specific drugs like high-intensity statins, ezetimibe, or PCSK9 inhibitors, there had been a notable lack of clinical evidence confirming whether achieving specific lower LDL targets directly improved patient outcomes.
Methodology
The Severance research team, led by Professors Kim Byeong-keuk, Lee Yong-joon, and Lee Seung-jun from the Department of Cardiology, conducted a comprehensive study involving 3,048 patients. This multi-center effort spanned across 17 medical institutions in Korea.
Patients were meticulously divided into two distinct groups:
- An intensive target group (aiming for LDL cholesterol below 55mg/dL).
- A conventional target group (aiming for LDL cholesterol below 70mg/dL).
To reach these ambitious objectives, physicians adjusted statin dosages and incorporated ezetimibe or PCSK9 inhibitors as required, ensuring a tailored approach for each patient.
Key Results
Following a three-year observation period, the incidence of major cardiovascular events—which included cardiovascular death, myocardial infarction, and stroke—was meticulously tracked.
The incidence was remarkably lower in the intensive target group at 6.6 percent. This figure was markedly lower than the 9.7 percent observed in the conventional group, showcasing a significant benefit.
Safety and Additional Benefits
Beyond the primary outcome, non-fatal myocardial infarction and revascularization rates were also consistently lower in the intensive target group. Importantly, the safety profiles remained consistent between the two groups concerning new-onset diabetes, muscle-related side effects, and liver enzyme elevation.
An additional positive finding indicated that the rate of creatinine elevation, associated with kidney function, was lower in the intensive group at 1.2 percent, compared to 2.7 percent in the conventional group.
Implications for Guidelines
Professor Kim stated that this study is the first to conclusively demonstrate that a more aggressive LDL cholesterol treatment strategy in patients with atherosclerotic cardiovascular disease leads to a practical reduction in cardiovascular events.
The compelling results provide a crucial evidence base supporting the stricter LDL cholesterol targets currently recommended in global treatment guidelines, affirming the importance of an intensive approach to managing cardiovascular risk.